<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642911</url>
  </required_header>
  <id_info>
    <org_study_id>UAB00171120-1</org_study_id>
    <nct_id>NCT04642911</nct_id>
  </id_info>
  <brief_title>Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy</brief_title>
  <acronym>AUB001</acronym>
  <official_title>Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy Using Autologous Mesenchymal Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ukraine Association of Biobank</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ukraine Association of Biobank</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, long term safety and efficacy follow up study for with insulin&#xD;
      dependent diabetes 2 type who have been treated with ex vivo gene therapy product in Ukraine&#xD;
      Association of Biobank bio-sponsored clinical studies. After completing the parent clinical&#xD;
      study (2 years),eligible subjects will be followed for an additional 8 years for total 10&#xD;
      years post-drugproduct infusion.&#xD;
&#xD;
      No investigation drug product will be administered in the study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 10, 2030</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study</measure>
    <time_frame>10 years post-drug product infusion</time_frame>
  </primary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Diabete Type 2</condition>
  <condition>Mesenchymal Stem Cell</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Long term follow up</intervention_name>
    <description>Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study</description>
    <other_name>LONG TERM</other_name>
    <other_name>FOLLOW UP</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with diabetic 2 type who have treated with gene therapy in a drug product&#xD;
        (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial&#xD;
        who agree to participate in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treated with gene therapy of diabetes 2 type in a drug product (Mesenchymal Stem Cell)&#xD;
             in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to&#xD;
             participate in this study&#xD;
&#xD;
          -  Able to comply with study requirements&#xD;
&#xD;
          -  Provision of written informed consent for this study by subjects or as applicable&#xD;
             subject legal/parent guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no exclusion criteria for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Bio-Stem Cell Rehabilitation</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

